Showing results (341-350 of 542) with videos related to
Sort By:
Pageof 55
Journal of the National Cancer Institute|February 8, 2007
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.Cancers|October 17, 2019
Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer CenterAlexandros Georgiou, Shelize Khakoo, Penelope Edwards, et al.Cancer Immunology Research|March 20, 2026
Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cellsDavid Cunningham, Junquan Liu, Inci Cevher Zeytin, et al.Annals of Surgical Oncology|October 18, 2022
The Cancer Hub Approach for Upper Gastrointestinal Surgery During COVID-19 Pandemic: Outcomes from a UK Cancer CentreJoseph P Doyle, Pranav H Patel, Sophie L F Doran, et al.Applied Health Economics and Health Policy|October 22, 2016
Ethical Hurdles in the Prioritization of Oncology CareFolkert de Groot, Stefano Capri, Jean-Claude Castanier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort studyAnthony J Swerdlow, Craig D Higgins, Paul Smith, et al.Molecular Cancer Therapeutics|July 3, 2019
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant CancersAdam Stewart, Elizabeth A Coker, Sebastian Pölsterl, et al.Oncotarget|February 11, 2016
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trialKhurum Khan, David Cunningham, Clare Peckitt, et al.Heart (British Cardiac Society)|July 24, 2014
Device-dependent association between paravalvar aortic regurgitation and outcome after TAVIRafal Dworakowski, Olaf Wendler, Brian Halliday, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusEric Van Cutsem, Claus-Henning Köhne, István Láng, et al.Pageof 55